Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Multicenter, Non-Randomized, Dose-Escalation and Dose-Expansion Study of Allogeneic Dual-Target Nectin-4/HER2 CAR-NK Cells Following Fludarabine/Cyclophosphamide Lymphodepletion in Adults With Relapsed/Refractory, Locally Advanced or Metastatic Urothelial Carcinoma

NCT07492628 is registered in ClinicalTrials.gov with Beijing Biotech as lead sponsor.

NCT NCT07492628
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07492628 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Multicenter, Non-Randomized, Dose-Escalation and Dose-Expansion Study of Allogeneic Dual-Target Nectin-4/HER2 CAR-NK Cells Following Fludarabine/Cyclophosphamide Lymphodepletion in Adults With Relapsed/Refractory, Locally Advanced or Metastatic Urothelial Carcinoma
Lead sponsor
Beijing Biotech
Phase
Phase 1
Overall status
Recruiting
Start date
March 2, 2026
Completion date
May 17, 2028
Enrollment
42 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, locally advanced urothelial carcinoma, metastatic urothelial carcinoma, upper tract urothelial carcinoma, urothelial carcinoma